PHIN-214
Prevention & Treatment of Decompensated Liver Cirrhosis
Phase 1Active
Key Facts
Indication
Prevention & Treatment of Decompensated Liver Cirrhosis
Phase
Phase 1
Status
Active
Company
About PharmaIN
PharmaIN is a private, clinical-stage biotech based in San Diego, leveraging expertise in peptide drug design and delivery to create convenient subcutaneous therapies for serious diseases. Its lead asset, PHIN-214, is in Phase 1 for liver cirrhosis, with data presented at major liver conferences. The company is actively seeking a strategic partner to advance its pipeline and has secured over $75M in funding from a mix of NIH grants, investors, and corporate partners.
View full company profile